靶向破局,CAR-T探路:重症肌无力治疗的范式跃迁

药创新
Dec 27, 2025

从“对症支持治疗”向“病因干预”的转变。撰文丨大眼怪近日,安进宣布,美国FDA已批准伊奈利珠单抗(Inebilizumab)用于治疗抗乙酰胆碱受体(AChR)抗体和抗肌肉特异性酪氨酸激酶(MuSK)抗体阳性的成人全身型重症肌无力(gMG)。该药物是目前首款且唯一获批复盖上述两种抗体阳性gMG人群的CD19靶向B细胞疗法。此次获批标志着,继FcRn拮抗剂之后,gMG治疗领域再添一款具有全新作用机制的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10